http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109021021-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0093 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109021021-B |
| titleOfInvention | 11, 12-dichlorobenzimidazole-1, 8-naphthalimide-platinum complex and preparation method and application thereof |
| abstract | The invention discloses an 11, 12-dichlorobenzimidazole-1, 8-naphthalimide-platinum complex and a preparation method and application thereof. The preparation method of the complex mainly comprises the following steps: putting a compound shown in a formula (II) and a compound shown in a formula (III) into an organic solvent, and carrying out a coordination reaction under the heating condition or the non-heating condition to obtain a target product. The complex has obviously higher inhibitory activity on certain cancer cells than that of a common antitumor drug cisplatin, and has lower toxicity on normal human liver cells HL-7702. The complex of the invention has a structure shown in the following formula (I), and the structures of the compound shown in the formula (II) and the compound shown in the formula (III) which are used as raw materials for preparing the complex are as follows: |
| priorityDate | 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.